Evidence mapPaperPMID 39940795Full record

ReviewInternational journal of molecular sciences2025

Fibrotic Changes in Rhegmatogenous Retinal Detachment.

Niina Harju, Anu Kauppinen, Sirpa Loukovaara

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Niina HarjuSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland.ORCID 0000-0001-9031-5353
Anu KauppinenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland.ORCID 0000-0001-8254-0200
Sirpa LoukovaaraUnit of Vitreoretinal Surgery, Department of Ophthalmology, Helsinki University Central Hospital, 00029 Helsinki, Finland.ORCID 0000-0002-2506-3900

Funding

Finnish Cultural FoundationHelsinki University Hospital Clinical Research Grants Y and TYH2023321Mary and Georg C. Ehrnrooth FoundationSilmä- ja KudospankkisäätiöSokeain Ystävät ry
6 · The paper itself

Abstract

Rhegmatogenous retinal detachment (RRD) is a sight-threatening condition involving retinal detachment and the accumulation of fluid in the subretinal space. Proliferative vitreoretinopathy (PVR) is a pathologic complication that develops after RRD surgery, and approximately 5-10% of RRD cases develop post-operative PVR. Prolonged inflammation in the wound healing process, epithelial-mesenchymal transition (EMT), retinal pigment epithelial (RPE) cell migration and proliferation, and epiretinal, intraretinal, and subretinal fibrosis are typical in the formation of PVR. RPE cells undergo EMT and become fibroblast-like cells that migrate to the retina and vitreous, promoting PVR formation. Fibroblasts transform into myofibroblasts, which promote fibrosis by overproducing the extracellular matrix (ECM). RPE cells, fibroblasts, glial cells, macrophages, T lymphocytes, and increased ECM production form contractile epiretinal membranes. Cytokine release, complement activation, RPE cells, glial cells, and endothelial cells are all involved in retinal immune responses. Normally, wounds heal within 4 to 6 weeks, including hemostasis, inflammation, proliferation, and remodeling phases. Properly initiated inflammation, complement activation, and the function of neutrophils and glial cells heal the wound in the first stage. In a retinal wound, glial cells proliferate and fill the injured area. Gliosis tries to protect the neurons and prevent damage, but it becomes harmful when it causes scarring. If healing is complicated, prolonged inflammation leads to pathological fibrosis. Currently, there is no preventive treatment for the formation of PVR, and it is worth studying in the future.

Indexed as

Retinal DetachmentVitreoretinopathy, ProliferativeAnimalsEpithelial-Mesenchymal TransitionFibroblastsFibrosisHumansRetinal Pigment Epitheliumepiretinal membraneepithelial–mesenchymal transitionfibrosisproliferative vitreoretinopathyrhegmatogenous retinal detachment

Identifiers

PMID39940795
PMCPMC11817287

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.